Compounds that obstruct the "landing gear" of a range of harmful viruses can successfully protect against infection by the virus that causes COVID-19, a study published today and led by Dana-Farber Cancer Institute scientists shows.
The approval of belzutifan, an oral hypoxia-inducible factor-2 alpha inhibitor, provides a new option for patients with advanced renal cell carcinoma (RCC) following treatment with a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
AUSTIN, Texas, Oct. 25, 2023 Aspira Women’s Health Inc. , a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic.
METHUEN — Nurses walked into Dana-Farber Cancer Institute – Merrimack Valley in pairs Monday to show their unity as they returned to work after their strike was followed by a